Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 5 th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

Oliver Meyer, Rudolf Schlag, Thomas Stauch, Bastian Fleischmann, Marcel Reiser, Dietrich Kaempfe, Timo Behlendorf, Manfred Welslau, Eyck von der Heyde, Steffen Dörfel, Claudia Willy, Martina Stauch

Blood (2022) 140 (Supplement 1): 2683–2684.

https://doi.org/10.1182/blood-2022-166741

Published: 2022

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 4 th Interim Analysis of the German Non-Interventional Trial RISA

Oliver Meyer, Rudolf Schlag, Thomas Stauch, Bastian Fleischmann, Marcel Reiser, Dietrich Kaempfe, Timo Behlendorf, Manfred Welslau, Claudia Willy, Martina Stauch

Blood (2021) 138 (Supplement 1): 3150.

https://doi.org/10.1182/blood-2021-146809

Published: 2021

Journal Articles

BCR-Assosiated Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia. Real World Experiences of a German Regional Clinical Register

Dietrich Kaempfe, MD, Roshanak Bob, MD, Joerg Brenn, Thomas Haverkamp, MD, Agnes Knopp, MD, Harald Stein, MD PhD Dr. h.c., Sebastian Böttcher, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-134686

Published: 2020

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3 rd Interim Analysis of the German Non-Interventional Trial RISA

Oliver Meyer, MD PhD, Martina Stauch, Dietrich Kaempfe, MD, Rudolf Schlag, Marcel Reiser, Eyck von der Heyde, Andreas Josting, Margarete Plath, Nadine Ballerstädt, Petra Stark-Lorenzen, Axel Matzdorff, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134542

Published: 2020

Journal Articles

Phenotypes of JAK2 -Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study

Tony Hennersdorf, Nadja Jaekel, Susann Schulze, MD, Dietrich Kaempfe, MD, Claudia Spohn, MD, Regina Moeller, MD, Maik Schwarz, MD, Hans-Juergen Hurtz, MD, Joern Ruessel, MD, Peter Tornow, Ute Neef, MD, Marion Schmalfeld, MD, Kathleen Jentsch-Ullrich, MD, Thoralf Lange, MD, Christian Junghanss, MD, Brigitte Kragl, MD, Haifa Kathrin Al-Ali, MD

Blood (2020) 136 (Supplement 1): 13.

https://doi.org/10.1182/blood-2020-139366

Published: 2020

Journal Articles

Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival

Blood (2008) 112 (11): 2966.

https://doi.org/10.1182/blood.V112.11.2966.2966

Published: 2008

Journal Articles

High Complete Remission Rate in Patients with Acute Myeloid Leukemia (AML) above the Age of 60 Years: A Report of the AML97#38 Study of the East German Hematology and Oncology Study Group.

Blood (2004) 104 (11): 880.

https://doi.org/10.1182/blood.V104.11.880.880

Published: 2004

NARROW

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 5 th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 4 th Interim Analysis of the German Non-Interventional Trial RISA

BCR-Assosiated Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia. Real World Experiences of a German Regional Clinical Register

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3 rd Interim Analysis of the German Non-Interventional Trial RISA

Phenotypes of JAK2 -Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study

Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival

High Complete Remission Rate in Patients with Acute Myeloid Leukemia (AML) above the Age of 60 Years: A Report of the AML97#38 Study of the East German Hematology and Oncology Study Group.

Email alerts

ASH Publications

American Society of Hematology

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 5 th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 4 th Interim Analysis of the German Non-Interventional Trial RISA

BCR-Assosiated Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia. Real World Experiences of a German Regional Clinical Register

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3 rd Interim Analysis of the German Non-Interventional Trial RISA

Phenotypes of JAK2 -Mutated Polycythemia Vera and Essential Thrombocythemia with and without Thromboembolic Events: Results of the Hinc-207 (OSHO #91) Study

Ten Year Follow up Analysis of the OSHO Phase III Trial (AML 96) Comparing Different Application Modes of AraC in Patients below 60 Years with Acute Myeloid Leukemia (AML): No Impact of AraCApplication Mode on Remission Rate, Toxicity, Disease-Free Survival or Overall Survival

High Complete Remission Rate in Patients with Acute Myeloid Leukemia (AML) above the Age of 60 Years: A Report of the AML97#38 Study of the East German Hematology and Oncology Study Group.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only